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ABSTRACT 
Sexually transmitted infections (STIs) represent a global health problem with variable 
prevalence depending on the geographical region and the type of population. Human 
papillomavirus (HPV) encompasses widespread virus types related to cervical carcinogenesis. 
The present study investigated the molecular prevalence of HPV and seven other important 
STIs in asymptomatic women working or studying at a Brazilian university. A secondary aim 
was to assess cytological abnormalities associated with HPV and other STIs coinfections. We 
recruited 210 women from a Brazilian university. HPV was detected using a single-round 
polymerase chain reaction (sPCR) followed by a viral genotyping by restriction fragment 
length polymorphism (RFLP-PCR). The presence of seven STIs: Chlamydia trachomatis, 
Neisseria gonorrhoeae, Treponema pallidum, Trichomonas vaginalis, Mycoplasma 
genitalium, herpes simplex virus (HSV)-1 and HSV-2 was detected by multiplex PCR 
(M-PCR). Furthermore, cytological findings and epidemiological characteristics were 
evaluated.The mean age of the participants was 27.1 years old. HPV prevalence was 33.8%, 
and HPV16 was the most frequently detected papillomavirus genotype. Moreover, multiple 
HPV infections were common (42.2%). We detected at least one STI agent in 11.4% of the 
tested women, most frequently C. trachomatis (6.7%). Among HPV-positive women, 14.1% 
were coinfected with other STI agents. Cytological abnormalities were observed in 9.5% of 
smears, and HPV-DNA, high-risk HPV (HR-HPV), HPV16 and HPV multiple infections 
were associated with abnormal cytological findings. There was a high prevalence of HPV, and 
C. trachomatis was the most prevalent STI agent, with low rates of cytological abnormalities. 
These findings highlight the need of timely STI diagnosis in young asymptomatic women 
and of a public policy design for STI prevention.
KEYWORDS: Sexually transmitted infections. Papillomavirus infections. Uterine cervical 
neoplasms. Screening. Polymerase chain reaction. 
INTRODUCTION
Sexually transmitted infections (STIs) represent a great global health problem 
directly impacting women’s sexual and reproductive health. More than one 
million individuals are infected daily by a STI worldwide, and approximately 
300 million people have acquired one of the four curable STIs, Chlamydia 
trachomatis (C. trachomatis), Neisseria gonorrhoeae (N. gonorrhoeae), Treponema 
pallidum (T. pallidum), and Trichomonas vaginalis (T. vaginalis). The incidence 
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of viral STIs is also high; every year an estimated over 
290 million individuals experience infections caused by 
human papillomavirus (HPV) worldwide1. The majority 
of infections caused by sexually curable agents are 
asymptomatic and treatable; however, when untreated 
or treated incorrectly, they can lead to severe health 
complications, particularly in women, such as infertility, 
pelvic inflammatory disease, ectopic pregnancy1,2, and an 
increased risk of human immunodeficiency virus (HIV) 
infection1,3. Therefore, it is urgent that the public health 
community make effective interventions for STI prevention, 
screening, diagnosis, and treatment available4.
Cervical cancer (CC) is the fourth most common 
neoplasm regarding the incidence and mortality in women 
worldwide5. HPV is necessary, but not sufficient for 
cervical carcinogenesis. Many factors may be associated 
with high-risk HPV (HR-HPV) and play an important role 
in viral persistence, contributing to cancer development6,7. 
Cofactors associated with the individual’s behaviours 
include the age at the first intercourse, multiple sexual 
partners, host genetic variability, and use of tobacco and oral 
contraceptives7-9. Furthermore, coinfection with bacterial 
vaginosis10 and other STIs may be associated with increased 
risk of high-grade squamous intraepithelial cervical lesions 
(HSIL) and squamous cervical cancer (SCC)11,12. 
STIs prevalence in women has been extensively 
investigated and presents with variable rates depending 
on the study population and the diagnostic methods 
employed11-13. However, prevalence studies on asymptomatic 
non-HPV STIs are scarce in university populations, as are 
investigations of HPV-related coinfections. 
The present study investigated the prevalence of HPV and 
seven other important STIs in asymptomatic women from a 
Parana State university, in Brazil. A secondary objective was 
to assess cytological abnormalities associated with HPV and 
other STIs coinfections. We detected a high prevalence of 
HPV and STIs, especially of C. trachomatis accompanied by 
low rates of cytological abnormalities, highlighting the need 
to adopt public policies for the prevention and early diagnosis 
of STIs in young and asymptomatic women. 
MATERIALS AND METHODS
Study population
In this transversal study, 210 women aged 18-50 years 
old were recruited by convenience between August 2014 
and November 2015. All participants had already had a 
sexual intercourse, lived in Maringa city, Parana State, 
Brazil, and were students or employees of the State 
University of Maringa (UEM), Parana State, Brazil. 
Any of the following factors were considered 
exclusion criteria: pregnancy, postpartum period, previous 
hysterectomy, vaginal bleeding, previous history of cancer, 
no history of sexual activity, recent treatment for any 
pathology of the urogenital tract, ablative or excisional 
therapy to the cervix within the previous 12 months, and 
no observation and/ or sample collection of squamous 
columnar junction (SCJ). 
All participants voluntarily provided a sample for the 
Papanicolaou (Pap) screening and HPV-DNA detection 
and non-HPV STIs detection; furthermore, all participants 
gave their written informed consent before the enrolment. 
The study was approved by the Committee for Ethics in 
Research Involving Humans of the State University of 
Maringa, UEM, Brazil (CAAE 30838314.9.0000.0104; 
permission 687.955/2014).
Study procedures
The participants answered a questionnaire on 
demographic characteristics, lifestyle and sexual behaviour. 
The information included age, self-declared skin color, 
marital status, childbirth, number of sexual partners during 
the lifespan, age of first intercourse, smoking habit, oral 
contraceptive use, and cervical cauterization.
Vaginal, cervical and endocervical samples were 
collected by the Ayres’s spatula and a cytobrush for 
the Pap smear preparation. Cytological smears were 
stained using the Papanicolaou technique and evaluated 
by a cytopathologist according to the Bethesda System 
diagnostic criteria14. The cytological findings were 
classified as negative for squamous intraepithelial lesion 
or malignancy (NILM), atypical squamous cells of 
undetermined significance (ASC-US) or could not exclude 
squamous intraepithelial lesions of high-grade (ASC-H), 
low-grade squamous intraepithelial lesions (LSIL), high-
grade squamous intraepithelial lesions (HSIL) and invasive 
cervical cancer (CC). The follow-up of positive patients 
(ASC-US or more severe cytologic changes) were carried 
out according to the Brazilian guidelines for CC screening15. 
For molecular procedures, samples were immediately 
suspended in 1.0 mL of sterile 0.9% NaCl
2 
solution and 
stored at - 80 º C until analysis. 
Genomic DNA extraction
Samples were incubated for 15 min with proteinase K in 
phosphate-buffered saline and then centrifuged for 30 s at 
6,800 g. DNA extraction was performed with the Purelink 
viral RNA/ DNA® kit (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA) according to the manufacturer’s 
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instructions. The quality and quantity of purified DNA 
were evaluated using a spectrophotometer (NanoDrop 2000 
Spectrophotometer, Thermo Fisher Scientific, Waltham, 
MA, USA).
Single-round PCR (sPCR) for HPV detection and 
HPV genotyping by restriction fragment length 
polymorphism (RFLP-PCR)
HPV was detected using a sPCR with the primers MY09 
(5'-CGTCCM AARGGAWACTGATC-3') and MY11 
(5'-GCMCAGGGWCATAAYAATGG-3') as described 
previously16. PCR was performed using the following 
conditions: 5 min of denaturation at 94 ºC; 30 cycles of 
denaturation at 94 ºC for 30 s, annealing at 55 ºC for 60 s, 
and extension at 72 ºC for 60 s; and a final extension step 
at 72 ºC for 8 min (Thermal cycler, Applied Biosystems, 
Foster City, CA, USA). This reaction produced a final 
amplification product of 450 base pairs (bp). The DNA 
quality was tested by the amplification of a 268 bp gene 
fragment of the human β-globin gene using the primers 
GH20 (5'-GAAGAGCCAAGGACAGGTAC-3') and PC04 
(5'-C AACTTCATCCACGTTCACC-3') under identical 
conditions as the ones of the HPV-PCR. Two types of 
controls were used in the reaction: a sample without DNA 
(negative control) and an HPV-positive cervical sample 
(positive control).
The final amplification products were loaded onto a 1% 
agarose gel stained with 150 ng/μL ethidium bromide and 
subjected to electrophoresis in a horizontal apparatus at 
110 V for 45 min in 0.5 × TBE buffer (45 mM Tris-borate, 
1 mM EDTA, pH 8.0). A 100 bp marker (Invitrogen, 
Thermo Fisher Scientific, Waltham, MA, USA) was used 
as a molecular size marker. The amplified DNA fragments 
were visualized in a transilluminator with UV light and 
photographed. 
HPV-positive samples were genotyped by RFLP 
analysis, in which amplified DNA was cleaved with 
restriction enzymes to generate DNA fragments of different 
molecular sizes. Aliquots of each amplification product 
were subjected to digestion with the restriction enzyme 
HpyCH4V (New England Biolabs, Ipswich, MA, USA)17. 
To better differentiate between HPV genotypes with similar 
RFLP patterns, such as HPV11/30, 18/68, 44/55 and 
61/83/84, a second restriction enzyme was used (NlaIII, 
New England Biolabs, Ipswich, MA, USA)18. The restriction 
digest fragments were then subjected to electrophoresis on 
8% polyacrylamide gels. Both, 100 and 25 bp ladders 
(Invitrogen, Carlsbad, CA, USA) were used as molecular 
sizemarkers. After electrophoresis, polyacrylamide gels 
were analysed with the LabImage ID software (Loccus 
Biotechnology, Cotia, Sao Paulo, Brazil), and the size of 
each fragment was determined. Genotyping was performed 
by comparing the molecular weights of the fragments for 
each HPV genotype as described by Santiago et al.17. A 
total of 40 individual HPV genotypes were determined 
by PCR-RFLP: 11 genotypes are considered high-risk 
(HR-HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56 and 58); 
11 are probably oncogenic (26, 30, 34, 53, 66, 67, 68, 69, 
70, 73and 82), and 18 are low-risk genotypes (LR-HPV) 
that are not associated with carcinogenesis (6, 11, 40, 42, 
43, 44, 54, 55, 61, 62, 64, 69, 72, 74, 81, 83, 84, and 91)19.
The patients positively diagnosed for HPV were 
requested to repeat the tests after 6 months, for the follow-
up and to verify the presence of viruses. 
Simultaneous detection of seven important STIs by 
multiplex PCR (M-PCR)
A M-PCR was performed to simultaneously detect 
C. trachomatis, N. gonorrhoeae, M. genitalium, T. vaginalis, 
HSV-1, HSV-2, and T. pallidum as previously described by 
Souza et al.13 (Table 1). M-PCR was carried out using the 
following conditions: 10 min of denaturation at 94 ºC; 
35 cycles of denaturation at 94 ºC for 60 s, annealing at 
62 ºC for 60 s, and extension at 72 ºC for 60 s; and a final 
extension step at 72 ºC for 10 min (Thermal cycler, Applied 
Biosystems, Thermo Fisher Scientific, Waltham, MA, 
USA). The M-PCR products were electrophoresed on an 
8% polyacrylamide gel. Positive controls for all analysed 
STIs were from positive clinical samples detected using 
reference methods, including culture and/ or sPCR. All 
clinical samples were also tested by using human β-globin-
specific primers and GH20/PC04 as an internal control 
of amplification and of DNA integrity, under the same 
conditions of the M-PCR. The patients positively diagnosed 
for ISTs were followed-up and treated according to the 
Brazilian Clinical Protocol and Therapeutic Guidelines20. 
Statistical analysis
Statistical analysis was performed with the software 
GraphPad Prism 6.0 (San Diego, California, USA), and 
the statistical significance was set at P <0.05. Different 
variables were evaluated for comparisons and analytical 
calculations based on the presence of HPV and STIs. A 
two-sided Fisher’s exact test with 2 × 2 contingency tables 
was used to evaluate statistically significant differences 
between groups. Crude odds ratios (OR) with 95% 
confidence intervals (CI) were calculated to estimate the 
association of HPV and STI positive results with different 
cytological findings.
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RESULTS
Population characteristics
A total of 210 women were enrolled in the study, 
including 166 students (79.0%), 26 employees (12.4%) 
and 18 participants who did not inform their roles at 
the University (8.6%). The mean age of the examined 
population was 27.1 years (range 18-50 years). The majority 
of the participants were white (85.2%), single (80.0%), 
and had never been pregnant (75.2%). Oral contraceptive 
use was frequent (60.0%), whereas smoking was relatively 
rare (8.1%). Most women (60.5%) had their first sexual 
intercourse before the age of 18 years old (range 13-39), 
the majority had a current sexual partner (72.4%) and more 
than one partner during their lives (68.1%) (Table 2). 
Prevalence of HPV and seven other important STIs 
HPV DNA was detected in 71 women (33.8%) aged 
25.9 ± 7.35 years, by means of sPCR. Twenty-nine HPV 
types were identified (Table 3), including 10 HR-HPV (16, 
18, 31, 33, 39, 45, 51, 56, 58, and 59), 7 probably oncogenic 
HPV (26, 66, 68, 69, 70, 73, and 82), and 12 LR-HPV (6, 
11, 13, 43, 54, 61, 62, 64, 72, 74, 81, and 83). HPV16 
(31.0%, n=22/71), HPV70 and HPV82 (11.3%, n=8/71 
each) represented the most frequently identified genotypes. 
HPV16 was the most common genotype in mono-infections, 
as well as in multiple infections with frequencies of 18.0% 
(n=13/71) and 12.7% (n=9/71), respectively.
Among HPV-DNA-positive women (n=71), HR-HPV 
genotypes, probably oncogenic types, and LR-HPV were 
detected in 59.1% (n=42/71), 16.9% (n=12/71) and 24% 
(n=17/71), respectively. Multiple HPV genotypes infections 
were very common, being detected in 42.2% of the total 
infections (n=30/71). Twenty-eight of these participants 
(93.3%) were infected by two HPV genotypes, and two 
patients (6.7%) by three HPV types. 
At least one STI agent was detected in 11.4% of the 
participants (n= 24/210) by M-PCR. The identified species 
included C. trachomatis (6.7%; n= 14/210), T. pallidum 
(1.9%; n= 4/210), HSV-2 (0.5%, n= 1/210), N. gonorrhoeae 
(0.5%, n= 1/210), T. vaginalis (0.5%, n= 1/210), HSV-1 
and M. genitalium coinfection (0.5%, n= 1/210), HSV-1 
and T. vaginalis coinfection (0.5%, n= 1/210), and HSV-2 
and N. gonorrhoeae coinfection (0.5%, n= 1/210). Figure 1 
shows the frequency of STI agents detected by M-PCR in 
all cases (n=24). All individuals who tested positive for 
STIs were asymptomatic.
Among HPV-positive women, 14.1% (n= 10/71) were 
coinfected with other STI agents. The most frequent 
coinfection was with C. trachomatis (50.0%; n= 5/10), 
followed by T. pallidum (20.0%; n= 2/10). N. gonorrhoeae, 
T. vaginalis, and M. genitalium coinfections with HSV-1 
were also observed (10.0%; n=1/10; one case each). The 
HPV genotypes implicated in STI coinfections are shown 
in Table 4. Table 2 shows the characteristics of women 
positive for HPV and STIs and that participants with 
25 years or younger as well as the ones that had more than 
one partner during their lives were associated with having 
HPV infection (P=0.02 for both analyses). 
Cytological findings
Most Pap smear results were NILM (90.5%, 
n=190/210). Cytological abnormalities were observed in 
Table 1 - Oligonucleotide primers used in the multiplex-PCR assays.





























CT = Chlamydia trachomatis; HSV-1/2 = Herpes simplex virus; MG = Micoplasma genitalium; NG = Neisseria gonorrhoeae; 
TP = Treponema pallidum; TV = Trichomonas vaginalis; Bp* = base pairs.
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9.5% (n=20/210) of the smears, including 15 women with 
ASC-US (7.1%, n=15/210) and five with LSIL (2.4%, 
n=5/210). No evidence of ASC-H, HSIL or CC was detected. 
Among the HPV-positive women, 76.1% (n=54/71) 
had NILM. Furthermore, 23.9% (n=17/71) presented 
with abnormal cytology, including 16.9% with ASC-US 
(n=12/71) and 7.0% with LSIL (n=5/71). In the positive 
women for STIs as determined by M-PCR, 87.5% had a 
NILM cytology (n=21/24), and among them three (12.5%) 
had cytological abnormalities, including two with ASC-US 
(8.3%) and one with LSIL (4.2%). Among women with 
ASC-US, one was positive for C. trachomatis and one for 
T. vaginalis, whereas the woman with LSIL was positive 
for C. trachomatis.
Table 5 shows the statistically significant association of 
HPV-DNA, HR-HPV, HPV16 and HPV-multiple infections 
with the presence of cytological abnormalities in the 
Pap test (P<0.0001; P<0.0001; P< 0.0001 and P=0.001 
respectively). There was a marginal statistical difference in 
the presence of coinfection of HPV and other STI agents 
with abnormal cytology (P= 0.056). 
DISCUSSION
The present study shows a prevalence of HPV-DNA 
(33.8%) and seven other important STIs (11.4%), including 
C. trachomatis, N. gonorrhoeae, M. genitalium, T. vaginalis, 
HSV-1, HSV-2, and T. pallidum, in asymptomatic women 












n (%) n (%)
Age (years)
≤ 25 122 (58.1) 73 (52.5) 49 (69.0) 0.02 106 (57.0) 16 (66.7) 0.39
25 88 (41.9) 66 (47.5) 22 (31.0) 80 (43.0) 8 (33.3)
Skin color*
White 179 (85.2) 119 (85.6) 60 (84.5) 0.54 159 (85.5) 20 (83.3) 0.16
Not white 12 (5.7) 7 (5.0) 5 (7.0) 9 (4.8) 3 (12.5)
Civil status*
Single 168 (80.0) 108 (77.7) 60 (84.5) 0.23 145 (77.9) 23 (95.8) -
Married 33 (15.7) 25 (18.0) 8 (11.3) 33 (17.7) 0.0 (0)
Number of pregnancies*
0 158 (75.2) 101 (72.7) 57 (44.5) 0.32 136 (73.1) 22 (91.7) 0.08
≥ 1 35 (16.7) 26 (18.7) 9 (12.7) 34 (18.3) 1 (4.2)
Age of first sexual intercourse*
≤ 18 127 (60.5) 80 (57.5) 47 (66.2) 0.21 112 (60.2) 15 (62.5) > 0.99
18 71 (33.8) 51 (36.7) 20 (28.2) 74 (39.8) 9 (37.5)
Smoking habit*
Yes 17 (8.1) 10 (7.2) 7 (9.9) 0.59 15 (8.1) 2 (8.3) >0.99
No 182 (86.7) 122 (87.8) 60 (84.5) 161 (86.6) 21 (87.5)
Oral contraceptive use*
Yes 126 (60.0) 80 (57.5) 46 (64.8) 0.44 110 (59.1) 16 (66.7) 0.49
No 79 (37.6) 55 (39.6) 24 (33.8) 72 (38.7) 7 (29.2)
Current sexual partner*
Yes 152 (72.4) 104 (74.8) 48 (67.6) 0.29 137 (73.6) 15 (62.5) 0.19
No 47 (22.4) 28 (20.1) 19 (26.8) 39 (21.0) 8 (33.3)
More than one partner during the life*
Yes 143 (68.1) 87 (62.6) 56 (78.9) 0.02 128 (68.8) 15 (62.5) 0.32
No 51 (24.3) 40 (28.8) 11 (15.5) 43 (23.1) 8 (33.3)
*Certain data were not informed by the participants of the study.
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at a Brazilian university. The majority of participants 
were students (79.0%) and most positive women for HPV 
and STIs were younger than 25 years (69.0% and 66.7%, 
respectively). Although we have detected a high prevalence 
of HPV, the rate of cervical cytological abnormalities 
was low (9.5%). Furthermore, the rates of HPV-multiple 
infections were also high (42.2%) while the most prevalent 
HPV was HPV16. 
In our study, the HPV rate was high as was the case 
of other Brazilian universities in the Northern and Central 
regions, in which frequencies of 25.5% and 47% were 
found, respectively21,22. Studies carried out at universities 
in different regions of the world found rates similar to 
ours23,24. In general, HPV prevalence studies have shown 
that the HPV-DNA detection rate in cervical specimens 
may vary depending on the investigated geographic place, 
with a higher prevalence in younger women aged 25 or 
less, which later decreases visibly in middle-age women25. 
The identification of HPV genotypes is relevant for the 
prophylaxis and treatment of the disease. The detection of 
HR-HPV is very important due to its greater propensity to 
persist and lead to the development of precancerous lesions 
and CC6,7,8,25. In our study, 59.1% of the HPV-positive 
women presented with HR-HPVs; genotype 16 was the 
most common among the genotypes and was followed by 
genotypes 70 and 82. Worldwide data on HPV genotypes 
prevalence have shown that genotype 16 is most widely 
distributed globally, followed by genotype 18; these two 
together are responsible for about 71% of all cervical 
cancers. Furthermore, the second most frequent HPV 
genotype may vary in different geographical regions25. 
Interestingly, the other HPV genotypes that were more 
commonly observed in our study (HPV70 and HPV82) 
are classified as probably oncogenic genotypes and are not 
included in currently available HPV vaccines. 
The presence of multiple HPV genotypes was frequent 
in our study (42.2%). Previous investigations of Brazilian 
university students have shown the presence of multiple 
HPV genotypes infection in 41% to 54.3% of women21,22. 
C. trachomatis, T. pallidum, N. gonorrhoeae, T. vaginalis, 
HSV-2, and coinfections between HSV-1 and T. vaginalis, 
HSV-1 and M. genitalium, and finally N. gonorrhoeae and 
HSV-2 were detected in this study. Among young women, 
genital C. trachomatis is the most prevalent bacterial STI1. 
Accordingly, in our investigation C. trachomatis was the 
most frequent species (6.7%), followed by T. pallidum. 
C. trachomatis prevalence in asymptomatic women 
has already been examined26,27. In studies conducted in 
different Brazilian regions, C. trachomatis genital infection 
rates varied and these differences may be related to the 
methodology of detection and the population profile12,27,28. 
The mean age among women infected with C. trachomatis 
in our study was low (25.7 years); this finding is in 
agreement with the majority of previous reports on the 
association of C. trachomatis infection and younger age in 
women26,28. Although most C. trachomatis cases are poorly 
symptomatic, a chronic and persistent infection may lead to 
Table 3 - Identification of HPV genotypes according to their 
oncogenic potential (oncogenic, probably oncogenic, and 
non-oncogenic genotypes) in the total of HPV-positive women 
group (n=71).
HPV genotypes Total HPV+ group (n=71)*
N %
































*This group considered the coinfections with more than one 
HPV genotype (multiple infections).
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severe complications for women’s health2,20. Therefore, it 
is extremely important to diagnose this infection in young 
asymptomatic women. In this sense, currently, there has 
been a great advance and improvement in C. trachomatis 
control, and prevention programs worldwide recommend 
that all sexually active females of 25 years of age or younger 
should undergo an annual screening29,30.
The number of T. pallidum infected individuals is 
increasing in many countries, emphasizing the need of early 
diagnoses2. In the present study, the prevalence of syphilis 
was 1.9%. Similar results were obtained by Abreu et al.31 
(1.7%) in Brazilian women using PCR-based methods. And 
other Brazilian studies obtained lower results in women 
tested by serological methods32,33. 
N. gonorrhoeae, T. vaginalis, HSV1/2, and M. 
genitalium were also detected in the present study. They 
have been frequently investigated with different prevalence 
rates depending on the population characteristics and 
methodology6,31,34,35.
Several authors have found an association of host 
epidemiological characteristics such as multiple sexual 
partners, smoking habit, oral contraceptive use, and age 
of the first sexual intercourse6,36 with persistence of HPV. 
However, many studies have not replicated this association; 
therefore, there is no consensus regarding the cofactors 
leading to the persistence of HPV infection7,36. Our analysis 
showed an association with the presence of HPV for age 
groups younger than 25 years and those women who had 
more than one partner during their lives. 
The vast majority (90.5%) of women in this study did 
not present with cytological abnormalities and among them, 
28.4% were HPV-DNA-positive. Similar results regarding 
the lack of cytological changes have been shown by another 
study conducted among university students from Northern 
Brazil; the authors found no cytological abnormalities in 
85.7% of women, and 23.4% of them were HPV-positive21. 
An investigation involving university women in Central 
Brazil observed high rates of HPV in participants with 
normal cytology22. 
In a meta-analysis of worldwide data, Bruni et al.37 
showed that only 11.7% of women with normal cytology 
had detectable DNA-HPV; however, in the current study the 
mean population age was different. Thus, it appears that in 
younger women, the rate of HPV associated with normal 
cytological findings is higher, so that the estimate of HPV 
infection in NILM can vary among populations depending 
on the geographical region and age25,37. Furthermore, only 
about 10-30% of women with detectable HPV-DNA show 







16, 18, 45, 
59
70 11, 43
N. gonorrhoeae 51 68 -
T. pallidum 16 66 -
T. vaginalis 16 - -
HSV-1/M. genitalium 16 - -
HSV-1/2 = Herpes simplex virus; HR-HPV = High-risk HPV; 
LR-HPV = Low-risk HPV
Figure 1 - Prevalence of non-HPV STIs agents in STI-positive women (n=24). Infections were assessed by multiplex-PCR.
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cytological abnormalities25, and our results corroborated 
these data.
In the present study, abnormal cytology was found 
in 9.5% of women, represented by 7.1% ASC-US and 
2.4% LSIL. Vieira et al.21 have shown a low prevalence of 
abnormal cytology (2.3% for HSIL, 0.4% for ASC-H, 6.4% 
for LSIL, and 5.3% for ASC-US) among university students, 
in Brazil. Rabelo-Santos et al.22 detected cytological 
abnormalities in 8.7% of all suitable cervical university 
students’ smears in a study conducted in Central Brazil, and 
HSIL was not present. In Canada, an investigation found a 
prevalence of 7.2% ASC-US, 3.4% LSIL, and 0.8% HSIL in 
the same type of population24. Cervical abnormalities may 
develop decades after the HPV infection and are, therefore, 
less frequent in younger populations. Among abnormal 
cytological findings, the majority (85.0%) were positive 
for HPV-DNA as expected38.
The statistical analysis showed that the detection of 
HPV, HR-HPV, HPV16 and multiple HPV infections were 
associated with the presence of cytological abnormalities. 
Our results are in accordance with several studies 
demonstrating this correlation10,12,39. 
A marginal statistical significance between HPV 
associated with other STIs was observed according to the 
cytological findings. Several studies have reported that 
other STIs, especially C. trachomatis, increase the risk of 
acquiring an HPV infection and/ or are associated with the 
development of intraepithelial lesions40,41, but others did 
not find this association42. 
CONCLUSION
The majority of HPV-positive patients did not 
return for follow-up so that it was not possible to verify 
data on the history of previous HPV infections from 
these women, which limits our interpretations on the 
persistence of HPV and its influence on the genesis of 
cytological abnormalities. In addition, the frequency of 
coinfections between HPV and other STI agents was low 
to enable a suitable evaluation on the influence of this 
association in abnormal cytology findings. In conclusion, 
the present study has shown a high prevalence of HPV 
and C. trachomatis as important STI agents, in younger 
asymptomatic university women accompanied by low rates 
of cytological abnormalities. Multiple HPV infections 
were also frequent, and the most prevalent genotype was 
HPV16. These results highlight the need to adopt public 
policies for the prevention and early diagnosis of STIs in 
young and asymptomatic women and to prevent future 
consequences, including the development of cervical 
lesions and cancer.







(n=20) OR (95% CI) P
n (%)
HPV-DNA 71 (33.8) 54 (28.4) 17 (85.0) 14.27 (4.23-46.91) <0.0001
LR-HPV 17 (24) 14 (7.4) 3 (15.0) 1.12 (0.49-2.42) 0.83
Probably oncogenic 12 (16.9) 10 (5.3) 2 (10) 2.00 (0.41-8.51) 0.31
HR-HPV 42 (59.1) 30 (15.8) 12 (60.0) 8.00 (3.02-21.25) <0.0001
HPV 16 22 (31.0) 12 (6.3) 10 (50.0) 14.83 (5.39-42,92) <0.0001
HPV multiple infections 30 (42.2) 23 (12.1) 7 (35.0) 3.91 (1.49-10.83) 0.001
HPV and STI 10 (4.8) 7 (3.7) 3(15.0) 4.61 (1.19-19.60) 0.056
Non-HPV STIs 24 (11.4) 21 (11.0) 3 (15.0) 1.42 (0.41-4.67) 0.70
Chlamydia trachomatis 14 (58.3) 12(6.3) 2 (10) 1.64 (0.34-6.58) 0.62
HSV-2 1 (4.2) 1 (0.5) - - -
Neisseria gonorrhoeae 1 (4.2) 1(0.5) - - -
Treponema pallidum 4 (16.7) 4 (2.1) - - -
Trichomonas vaginalis 1 (4.2) - 1 (5.0) - -
HSV-1 and T. vaginalis 1 (4.2) 1 (0.5) - - -
HSV-1 and M. genitalium 1 (4.2) 1 (0.5) - - -
HSV-2 and N. gonorrhoeae 1 (4.2) 1 (0.5) - - -
LR-HPV = Low-risk HPV; HR-HPV = High-risk HPV; HSV = 1/2-Herpes simplex virus
Rev Inst Med Trop São Paulo. 2021;63:e1
High molecular prevalence of HPV and other sexually transmitted infections
Page 9 of 10
ACKNOWLEDGMENTS
This work was supported by Conselho Nacional de 
Desenvolvimento Cientifico e Tecnologico (CNPq), grant 
Nº 484994/2013-1.
AUTHORS’ CONTRIBUTIONS
MEL and VRSS conceived and designed the work, 
analysed and interpreted the data; CGB participated in the 
design of work and in the analysis and interpretation of data; 
TTS, FG and RPS performed the experimental procedures, 
acquisition and analysis of data; SKIT and RCCC assisted 
the patients and collected samples. MMTI performed the 
Pap test evaluation; TTS, MEL and VRSS wrote and revised 
the article. The authors approve the final version of the 
manuscript and are responsible for all its aspects.
CONFLICT OF INTERESTS
The authors declare no conflict of interests.
REFERENCES
 1. World Health Organization. Report on global sexually transmitted 
infection surveillance, 2018. Geneva: WHO; 2018. [cited 2020 
Dec 4]. Available from: https://apps.who.int/iris/bitstream/ha
ndle/10665/277258/9789241565691-eng.pdf?ua=1
 2. Centers for Disease Control and Prevention. Sexually transmitted 
disease surveillance 2017. Atlanta: CDC; 2018. [cited 2020 
Dec 4] Available from: https://www.cdc.gov/std/stats17/2017-
STD-Surveillance-Report_CDC-clearance-9.10.18.pdf
 3. Masha SC, Cools P, Sanders EJ, Vaneechoutee M, Crucitti 
T. Trichomonas vaginalis and HIV infection acquisition: 
a systematic review and meta-analysis. Sex Trans Infect. 
2019;95:36-42.
 4. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo 
M, Low N, et al. Global estimates of the prevalence and 
incidence of four curable sexually transmitted infections in 
2012 based on systematic review and global reporting. PLoS 
One. 2015;10:e0143304.
 5. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, 
Piñeros M, et al. Estimating the global cancer incidence and 
mortality in 2018: GLOBOCAN sources and methods. Int J 
Cancer. 2019;44:1941-53.
 6. Verteramo R, Pierangeli A, Mancini E, Calzolari E, Bucci M, Osborn 
J, et al. Human Papillomaviruses and genital co-infections in 
gynaecological outpatients. BMC Infect Dis. 2009;9:16.
 7. Ribeiro AA, Costa MC, Alves RR, Villa LL, Saddi VA, Carneiro 
MA, et al. HPV infection and cervical neoplasia: associated 
risk factors. Infect Agent Cancer. 2015;10:16.
 8. International Collaboration of Epidemiological Studies of Cervical 
Cancer. Carcinoma of the cervix and tobacco smoking: 
collaborative reanalysis of individual data on 13,541 women 
with carcinoma of the cervix and 23,017 women without 
carcinoma of the cervix from 23 epidemiological studies. Int 
J Cancer. 2006;118:1481-95.
 9. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers 
JM, et al. Effect of oral contraceptives on risk of cervical cancer 
in women with human papillomavirus infection: the IARC 
multicentre case-control study. Lancet. 2002;359:1085-92.
 10. Suehiro TT, Malaguti N, Damke E, Uchimura NS, Gimenes 
F, Souza RP, et al. Association of human papillomavirus 
and bacterial vaginosis with increased risk of high-grade 
squamous intraepithelial cervical lesions. Int J Gynecol Cancer. 
2019;29:242-9.
 11. Zereu M, Zettler CG, Cambruzzi E, Zelmanowicz A. Herpes 
simplex virus type 2 and Chlamydia trachomatis in 
adenocarcinoma of the uterine cervix. Gynecol Oncol. 
2007;105:172-5.
 12. Abreu AL, Malaguti N, Souza RP, Uchimura NS, Ferreira EC, 
Pereira MW, et al. Association of human papillomavirus, 
Neisseria gonorrhoeae and Chlamydia trachomatis co-
infections on the risk of high-grade squamous intraepithelial 
cervical lesion. Am J Cancer Res. 2016;6:1371-83.
 13. Souza RP, Abreu AL, Ferreira EC, Rocha-Brischiliari SC, 
Carvalho MD, Pelloso SM, et al. Simultaneous detection of 
seven sexually transmitted agents in human immunodeficiency 
virus–infected Brazilian women by multiplex polymerase chain 
reaction. Am J Trop Med Hyg. 2013;89:1199-202.
 14. Solomon D, Nayar R. Sistema Bethesda para citopatologia 
cervicovaginal: definições, critérios e notas explicativas. 2ª ed. 
Rio de Janeiro: Revinter; 2005.
 15. Brasil. Ministério da Saúde. Instituto Nacional de Câncer 
José Alencar Gomes da Silva. Coordenação de Prevenção 
e Vigilância. Divisão de Detecção Precoce e Apoio à 
Organização de Rede. Diretrizes brasileiras para o rastreamento 
do câncer do colo do útero. 2ª ed. Rio de Janeiro: INCA; 




 16. Manos MM, Waldman J, Zhang TY, Greer CE, Eichinger G, 
Schiffman MH, et al. Epidemiology and partial nucleotide 
sequence of four novel genital human papillomaviruses. Infect 
Dis. 1994;170:1096-9.
 17. Santiago E, Camacho L, Junquera ML, Vázques F. Full HPV typing 
by a single restriction enzyme. J ClinVirol. 2006;37:38-46.
 18. Chen L, Watanabe K, Haruyama T, Kobayashi N. Simple and rapid 
human papillomavirus typing method by restriction fragment 
length polymorphism analysis with two restriction enzymes. 
J Med Virol. 2013;85:1229-34.
Suehiro et al.
Rev Inst Med Trop São Paulo. 2021;63:e1Page 10 of 10
 19. HPV Information Centre. [cited 2020 Dec 4]. Available from: 
https://hpvcentre.net/
 20. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
Departamento de DST, Aids e Hepatites Virais. Protocolo 
clínico e diretrizes terapêuticas para atenção integral às pessoas 
com infecções sexualmente transmissíveis. Brasília: Ministério 




 21. Vieira RC, Monteiro JS, Manso EP, Santos MR, Tsutsumi MY, 
Ishikawa EA, et al. Prevalence of type-specific HPV among 
female university students from northern Brazil. Infect Agent 
Cancer. 2015;10:21.
 22. Oliveira DF, Pereira RN, Alves RR, Saddi VA, Sousa NA, Ribeiro 
AA, et al. Association between human papillomavirus infection 
and cytological abnormalities in young female university 
students in Central Brazil. Cytol Histol Int J. 2017;1:000101.
 23. Auvinen E, Niemi M, Malm C, Zilliacus R, Trontti A, Fingerroos 
R, et al. High prevalence of HPV among female students in 
Finland. Scand J Infect Dis. 2005;37:873-6.
 24. Richardson H, Franco E, Pintos J, Bergeron J, Arella M, Tellier 
P. Determinants of low-risk and high-risk cervical human 
papillomavirus infections in Montreal university students. Sex 
Transm Dis. 2000;27:79-86.
 25. IARC Working Group on the Evaluation of Carcinogenic Risks 
to Humans. Biological agents: volume 100 B: a review of 
human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 
2012;100:1-441.
 26. Santos C, Teixeira F, Vicente A, Astolfi-Filho S. Detection of 
Chlamydia trachomatis in endocervical smears of sexually 
active women in Manaus-AM, Brazil, by PCR. Braz J Infect 
Dis. 2003;7:91-5
 27. Tavares MC, Macêdo JL, de Lima Junior SF, Heráclio SA, Amorim 
MM, Maia MM, et al. Chlamydia trachomatis infection and 
human papillomavirus in women with cervical neoplasia in 
Pernambuco-Brazil. Mol Biol Rep. 2014;41:865-74.
 28. Santos LM, Vieira MR, Oliveira JF, Trindade JQ, Brasiliense 
DM, Ferrari SF, et al. High prevalence of sexual Chlamydia 
trachomatis infection in young women from Marajó Island, in 
the Brazilian Amazon. PLoS One. 2018;13:e0207853.
 29. Public Health England. National chlamydia screening programme 
standards. 7th ed. London: Public Health England; 2018. [cited 




 30. Keegan MB, Diedrich JT, Peipert JF. Chlamydia trachomatis 
infection: screening and management. J Clin Outcomes Manag. 
2014;21:30-8. 
 31. Abreu A, Souza R, Bonini M, Gimenes F, Consolaro ME. Human 
Papillomavirus and sexually transmitted infections in women 
with and without abnormalities in cervical cytology. Biochem 
Mol Biol J. 2015;29:LB126.
 32. Lima YA, Turchi MD, Fonseca ZC, Garcia FL, Cardoso FA, 
Reis MN, et al. Sexually transmitted bacterial infections 
among young women in Central Western Brazil. J Infect Dis. 
2014;25:16-21.
 33. Oliveira FA, Pfleger V, Lang K, Heukelbach J, Miralles I, Fraga F. 
et al. Sexually transmitted infections, bacterial vaginosis, and 
candidiasis in women of reproductive age in rural Northeast 
Brazil: a population-based study. Mem Inst Oswaldo Cruz. 
2007;102:751-6.
 34. Seña AC, Lee JY, Schwebke J, Philip SS, Wiesenfeld HC, Rampalo 
AM, et al. A silent epidemic: the prevalence, incidence 
and persistence of Mycoplasma genitalium among young, 
asymptomatic high-risk women in the United States. Clin 
Infect Dis. 2018;67:73-9.
 35. Francis SC, Mthiyane TN, Baisley K, Mchunu SL, Ferguson JB, 
Smit T, et al. Prevalence of sexually transmitted infections 
among young people in South Africa: a nested survey in 
a health and demographic surveillance site. PLoS Med. 
2018;15:e1002512.
 36. Fedrizzi EN, Schlup CG, Menezes ME, Campos M. Infecção pelo 
papilomavírus humano (HPV) em mulheres de Florianópolis, 
Santa Catarina. DST J Bras Doenças Sex Transm. 2008;20:73-
9.
 37. Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, Sanjosé 
S. Cervical human papillomavirus prevalence in 5 continents: 
meta-analysis of 1 million women with normal cytological 
findings. J Infect Dis. 2010;202:1789-99.
 38. Consolaro ME, Maria-Engler SS, organizadoras. Citologia clínica 
cérvico-vaginal: texto e atlas. São Paulo: Roca; 2012.
 39. Parthenis C, Panagopoulos P, Margari N,Kottaridi C, Spathis 
A, Pouliakis A, et al. The association between sexually 
transmitted infections, human papillomavirus, and cervical 
cytology abnormalities among women in Greece. Int J Infect 
Dis. 2018;73:72-7.
 40. Liu J, Liu W, Liu Y, Zhou X, Zhang Z, Sun Z. Prevalence of 
microorganisms co-infections in human papillomavirus 
infected women in Nothern China. Arch Gynecol Obstet. 
2016;293:595-602.
 41. Karim S, Souho T, Benlemlih M, Bennani B. Cervical cancer 
induction enhancement potential of Chlamydia trachomatis: 
a systematic review. Curr Microbiol. 2018;75:1667-74.
 42. Magalhaes PA, Miranda CA, Lima EG, Moizéis RN, Lima DB, 
Cobucci RN, et al. Genital tract infection with Chlamydia 
trachomatis in women attended at a cervical cancer screening 
program in Northeastern from Brazil. Arch Gynecol Obst. 
2015;291:1095-102.
